📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Simulations Plus shares target raised with Buy rating on acquisition

EditorAhmed Abdulazez Abdulkadir
Published 2024-06-13, 09:52 a/m
SLP
-

On Wednesday, Craig-Hallum adjusted its outlook on Simulations Plus (NASDAQ:SLP), increasing the price target to $56 from the previous $51, while maintaining a Buy rating on the stock. This change follows the company's announcement on Tuesday that it had acquired Pro-ficiency for $100 million in cash.

The acquisition marks a significant move for Simulations Plus, diverging from its pattern of smaller, supplemental purchases to a deal that considerably extends its market reach. Pro-ficiency's integration is expected to double Simulations Plus's total addressable market (TAM) to $8 billion, add over $15 million in revenues, and be accretive to the fiscal year 2025 earnings per share (EPS).

Simulations Plus's financial position appears robust, with $119 million in cash reported at the end of the second quarter, and a strong record of positive free cash flow. The successful acquisition of Immunetrics last year has set a precedent for strategic growth through mergers and acquisitions.

This latest move is poised to significantly enhance the company's drug development services, spanning from pre-clinical stages to product commercialization. By integrating AI-driven simulation-enabled performance and intelligence solutions, Simulations Plus aims to bolster its offerings in the market. Additionally, the acquisition is expected to reinforce the company's capabilities in data analytics and outcomes, improving the efficiency of the drug development process.

In other recent news, Simulations Plus has seen significant developments. The company's revenue for the second quarter of fiscal 2024 increased by 16%, with its services segment showing a notable 27% increase. The firm has also expanded its market reach by acquiring Pro-ficiency Holdings, Inc. for $100 million, a strategic move that is expected to double the company's total addressable market to $8 billion.

Oppenheimer has raised its price target on shares of Simulations Plus following the acquisition, reflecting confidence in the company's growth prospects. The U.S. Food and Drug Administration (FDA) has also renewed its license for Simulations Plus's DILIsym software platform, marking a continued partnership.

InvestingPro Insights

Following the positive outlook from Craig-Hallum on Simulations Plus (NASDAQ:SLP), current data from InvestingPro underscores the company's financial landscape. With a market capitalization of approximately $984.46 million, Simulations Plus is trading at a P/E ratio of 94.08, indicating a high valuation compared to earnings. Despite this, the company's strong gross profit margin of 75.14% over the last twelve months as of Q2 2024, and a revenue growth of 18.86% in the same period, reflect its solid operational efficiency and expansion.

InvestingPro Tips highlight that Simulations Plus has more cash than debt on its balance sheet and has maintained dividend payments for 13 consecutive years, which is a testament to its financial stability and commitment to shareholder returns. Additionally, the company's liquid assets exceed its short-term obligations, providing flexibility for future investments or acquisitions. For readers interested in a deeper analysis, there are over 10 additional InvestingPro Tips available, offering insights that can guide investment decisions. To access these tips, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.

As Simulations Plus navigates its growth trajectory with recent acquisitions, these financial metrics and InvestingPro Tips provide valuable context for investors weighing the company's future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.